Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Kyowa Kirin Co., Ltd.
  6. Summary
    4151   JP3256000005

KYOWA KIRIN CO., LTD.

(4151)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
09/16/2021 09/17/2021 09/21/2021 09/22/2021 09/24/2021 Date
4080 4100 4130 4105 4210 Last
645800 1078000 893800 691500 833600 Volume
0.00% +0.49% +0.73% -0.61% +2.56% Change
Estimated financial data (e)
Sales 2021 351 B 3 178 M 3 178 M
Net income 2021 51 627 M 467 M 467 M
Net cash position 2021 295 B 2 663 M 2 663 M
P/E ratio 2021 43,8x
Yield 2021 1,09%
Sales 2022 384 B 3 473 M 3 473 M
Net income 2022 64 048 M 579 M 579 M
Net cash position 2022 314 B 2 839 M 2 839 M
P/E ratio 2022 35,3x
Yield 2022 1,20%
Capitalization 2 262 B 20 432 M 20 456 M
EV / Sales 2021 5,60x
EV / Sales 2022 5,07x
Nbr of Employees 5 423
Free-Float 45,8%
More Financials
Company
Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Ratings of Kyowa Kirin Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about KYOWA KIRIN CO., LTD.
09/24KYOWA KIRIN : Long-Term CRYSVITA« ▼ (burosumab) Treatment Reduces the Burden of Dise..
BU
09/24Kyowa Kirin Co., Ltd. Announces Publication of New Data Highlighting the Sustained Bene..
CI
09/13KYOWA KIRIN : to Present Atopic Dermatitis Clinical Data from KHK4083/AMG 451 Phase 2 Stud..
BU
09/13Kyowa Kirin Co., Ltd. to Present Atopic Dermatitis Clinical Data from Khk4083/Amg 451 P..
CI
09/13Kyowa Kirin Initiates Phase 2 Clinical Study of G-Lasta« for the Mobilization of Hemato..
CI
09/08AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilo..
CI
09/01Kyowa Kirin Announces NDA Submission of Automated Injection Device of G-Lasta in Japan
CI
08/17MEI PHARMA : Doses First Patient in Phase 3 Study of Zandelisib in Lymphoma Patients
MT
08/17MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 ..
CI
08/03Kyowa Kirin Co., Ltd. Announces Earnings Results for the Second Quarter of the Fiscal Y..
CI
08/03KYOWA KIRIN : Appendix to the Consolidated Financial Summary Fiscal 2021 Interim
PU
08/03KYOWA KIRIN : Consolidated Financial Summary Fiscal 2021 Second Quarter
PU
07/29Kyowa Kirin Announces NDA Submission of Bardoxolone Methyl for Alport Syndrome in Japan
AQ
07/23KYOWA KIRIN : Provides Update on Application for Marketing Authorisation of Istradefylline..
BU
07/23Kyowa Kirin Co., Ltd. Provides Update on Application for Marketing Authorisation of Ist..
CI
More news
News in other languages on KYOWA KIRIN CO., LTD.
09/24KYOWA KIRIN : Die Langzeitbehandlung mit CRYSVITA« ▼ (Burosumab) verringert die Bela..
07/20KYOWA KIRIN : gibt EU-Zulassung für die Selbstverabreichung von CRYSVITA« ▼ (Burosum..
06/02MÄRKTE ASIEN/Starke BIP-Daten schieben Sydney auf Rekordhoch
06/02MÄRKTE ASIEN/Uneinheitlich - Starke BIP-Daten schieben Sydney an
06/01Hoy en Wall Street: Nuevos retos para los mercados
More news
Chart KYOWA KIRIN CO., LTD.
Duration : Period :
Kyowa Kirin Co., Ltd. Technical Analysis Chart | 4151 | JP3256000005 | MarketScreener
Technical analysis trends KYOWA KIRIN CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 4 210,00 JPY
Average target price 4 115,00 JPY
Spread / Average Target -2,26%
EPS Revisions
Managers and Directors
Masashi Miyamoto President, CEO & Representative Director
Motohiko Kawaguchi Executive Officer, Manager-Accounting & Finance
Nobuo Hanai Chairman
Mitsuo Satoh Executive Officer, GM-Research & Development
Kentaro Uryu Independent Outside Director
Sector and Competitors